Abstract：Objective To explore the optimal local treatment pattern of supraclavicular lymph node in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis (sISLM). Methods Clinical data of 128 breast cancer patients with sISLM admitted to the Fourth Hospital of Hebei Medical University from 2010 to 2015 were retrospectively analyzed. Among them, 68 cases were treated with supraclavicular lymph node dissection combined with radiotherapy, and 60 cases received radiotherapy alone. The locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS) were statistically compared between two groups. Results Univariate analysis demonstrated that the 5-year LRFS,DMFS,PFS and OS did not significantly differ between two groups (all P>0.05). Multivariate analysis revealed that the local treatment pattern of supraclavicular lymph node was an independent prognostic factor for the 5-year DMFS, PFS and OS (all P<0.05). Subgroup analysis showed that when radiotherapy alone was performed, the 5-year OS of patients in the supraclavicular region radiation doseof>50Gy group were significantly better than that in the 50Gy group (P=0.047). When supraclavicular lymph node dissection combined with radiotherapy was delivered, if the number of dissection was less than 10, the 5-year LRFS, DMFS, PFS, OS of patients in the>50Gy group were all better than those in the 50Gy group numerically without statistical significance (all P>0.05). If the number of dissection was ≥10, the 5-year LRFS, DMFS, PFS, OS in the 50Gy group were better than those in the>50Gy group numerically, whereas significant difference was only found in the 5-year DMFS (P=0.028). Conclusions Supraclavicular lymph node dissection combined with radiotherapy may be the optimal local treatment pattern for supraclavicular lymph node. When radiotherapy alone is performed, a radiation boost to the supraclavicular region may improve OS. When supraclavicular lymph node dissection combined with radiotherapy is performed, if the degree of dissection is low, a radiation boost to the supraclavicular region may bring clinical benefits. However, if the degree of dissection is high, a radiation boost to the supraclavicular region may not bring significant clinical benefits.
Liu Zhikun,Li Xiaohong,Zhu Longyu et al. Comparison of different local treatment patterns in breast cancer with ipsilateral supraclavicular lymph node metastasis[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 462-467.
[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.008. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.008. [2] Fan Y, Xu B, Liao Y, et al. A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients[J]. Breast, 2010, 19(5):365-369. DOI:10.1016/j.breast.2010.03.022. [3] Chen SC, Chen MF, Hwang TL, et al. Prediction of supraclavicular lymph node metastasis in breast carcinoma[J]. Int J Radiat Oncol Biol Phys, 2002, 52(3):614-619. DOI:10.1016/s0360-3016(01)02680-3. [4] Jackson SM. Carcinoma of the breast-the significance of supraclavicular lymph node metastases[J]. Clin Radiol, 1966, 17(2):107-114. DOI:10.1016/s0009-9260(66)80066-1. [5] Kiricuta IC, Willner J, Kölbl O, et al. The prognostic significance of the supraclavicular lymph node metastases in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 1994, 28(2):387-393. DOI:10.1016/0360-3016(94)90062-0. [6] Debois JM. The significance of supraclavicular node metastasis in patients with breast cancer:a literature review[J]. Strahlenther Onkol, 1997, 173(1):1-12. DOI:10.1007/BF03039187. [7] Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases:the University of Texas M. D. Anderson Cancer Center experience[J]. J Clin Oncol, 2001, 19(3):628-633. DOI:10.1200/JCO.2001.19.3.628. [8] Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer[J]. J Clin Oncol, 2002, 20(17):3628-3636. DOI:10.1200/JCO.2002.02.026. [9] Chen SC, Chang HK, Lin YC, et al. Prognosis of breast cancer after supraclavicular lymph node metastasis:not a distant metastasis[J]. Ann Surg Oncol, 2006, 13(11):1457-1465. DOI:10.1245/s10434-006-9012-1. [10] Grotenhuis BA, Klem TM, Vrijland WW. Treatment outcome in breast cancer patients with ipsilateral supraclavicular lymph node metastasis at time of diagnosis:a review of the literature[J]. Eur J Surg Oncol, 2013, 39(3):207-212. DOI:10.1016/j.ejso.2012.11.002. [11] Liu XH, ZhangL, Chen B. A meta-analysis of the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node metastasis versus patients with stage ⅢB/c or Ⅳ breast cancer[J]. Chronic Dis Transl Med, 2015, 1(4):236-242. DOI:10.1016/j.cdtm.2016.01.002. [12] Park HJ, Shin KH, Cho KH, et al. Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2011, 81(5):e689-695. DOI:10.1016/j.ijrobp.2010.11.061. [13] 李帅,王淑莲,宋永文,等. 初诊同侧锁骨上淋巴结转移乳腺癌综合治疗疗效[J]. 中华放射肿瘤学杂志, 2019, 28(1):17-22. DOI:10.3760/cma.j.issn.1004-4221.2019.01.004. Li S, Wang SL, Song YW, et al. Clinical efficacy and prognosis of breast cancer patients with ipsilateral supraclavicular lymph node metastases treated with multi-modality therapy at diagnosis[J]. Chin J Radiat Oncol, 2019, 28(1):17-22. DOI:10.3760/cma.j.issn.1004-4221.2019.01.004. [14] Pergolizzi S, Settineri N, Santacaterina A, et al. Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy[J]. Ann Oncol, 2001, 12(8):1091-1095. DOI:10.1023/a:1011624401595. [15] Wu SG, Sun JY, Zhou J,et al. The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis:a retrospective analysis of Chinese patients[J]. Onco Targets Ther, 2014, 7:281-288. DOI:10.2147/OTT. S56596. [16] Jung J, Kim SS, Ahn SD, et al. Treatment outcome of breast cancer with pathologically proven synchronous ipsilateral supraclavicular lymph node metastases[J]. J Breast Cancer, 2015, 18(2):167-172. DOI:10.4048/jbc.2015.18.2.167. [17] Chen QT, Zeng LY, Ouyang DJ, et al. Surgery of the primary tumor offers survival benefits of breast cancer with synchronous ipsilateral supraclavicular lymph node metastasis[J]. World J Surg, 2020, 44(4):1163-1172. DOI:10.1007/s00268-019-05293-4. [18] Chang XZ, Yin J, Sun J, et al. A retrospective study of different local treatments in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis[J]. J Cancer Res Ther, 2013, 9(Suppl):S158-161. DOI:10.4103/0973-1482.122514. [19] 姚智敏. 乳腺癌锁骨上淋巴结清扫与生存关系的Meta分析[D]. 沈阳:中国医科大学, 2014. Yao ZM. Meta-analysis of the relationship between supraclavicular lymph node dissection and survival in breast cancer[D]. Shenyang:China Medical University, 2014. [20] Zhang W, Qi XM, Chen AX, et al. The role of supraclavicular lymph node dissection in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis.[J]. Chin J Oncol, 2017, 39(5):374-379. DOI:10.3760/cma.j.issn.0253-3766.2017.05.011. [21] Kim K, Kim SS, Shin KH, et al. Aggressive surgical excision of supraclavicular lymph node did not improve the outcomes of breast cancer with supraclavicular lymph node involvement (KROG 16-14)[J]. Clin Breast Cancer, 2020, 20(1):51-60. DOI:10.1016/j.clbc.2019.09.004. [22] 焦得闯,朱久俊,乔江华,等. 新辅助化疗后乳腺癌同侧锁骨上淋巴结病理完全缓解影响因素分析[J]. 中华医学杂志, 2019, 99(38):2989-2993. DOI:10.3760/cma.j.issn.0376-2491.2019.38.005. Jiao DC, Zhu JJ, Qiao JH, et al. The influence factors of pathological complete response of the ipsilateral supraclavicular lymph node of breast cancer after neoadjuvant chemotherapy[J]. Natl Med J China, 2019, 99(38):2989-2993. DOI:10.3760/cma.j.issn.0376-2491.2019.38.005.
2021, Vol. 30 
